Parallax Health Sciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Parallax Health Sciences generated cash of -$2,945,573, which is less than the previous year. Cash used in financing activities reached the amount of $2,954,384 last year. Net change in cash is therefore $6,183.
Cash Flow
| 2012 | -238.98K | -2.18K | 114.5K |
|---|---|---|---|
| 2013 | -26.42K | 0 | 17.6K |
| 2014 | -56 | 0 | 0 |
| 2015 | -648.83K | -7.65K | 1.56M |
| 2016 | -835.77K | -94.64K | 80.45K |
| 2017 | -1.35M | 0 | 1.29M |
| 2018 | -1.29M | 0 | 1.33M |
| 2019 | -2.94M | -2.62K | 2.95M |
PRLX Cash Flow Statement (2012 – 2019)
| 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 262 | 183 | 63.36K | 912.39K | 513 | 569 | 9.39K | 136.06K |
Operating activities | ||||||||
Net income | -12.86M | 16.28M | -13.87M | -8.23M | -3.41M | -1.11M | -504.49K | -554.66K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 187.38K | 120.62K | 345.49K | 210.98K | 77.90K | 7.98K | 12.23K | 18.55K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47.37K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47.37K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 687.92K | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 410.14K | 302.94K | 82.68K | 0 | 0 | 0 |
Accounts payable | 45.79K | 2.13M | 3.03M | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -2.94M | -1.29M | -1.35M | -835.77K | -648.83K | -56 | -26.42K | -238.98K |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.62K | 0 | 0 | -94.64K | -7.65K | 0 | 0 | -2.18K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -2.62K | 0 | 0 | -94.64K | -7.65K | 0 | 0 | -2.18K |
Financing activities | ||||||||
Common Stock Issued | 2.33M | 41.25K | 201.5K | 0 | 37.98K | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -59.24K | 0 | -785.04K | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.95M | 1.33M | 1.29M | 80.45K | 1.56M | 0 | 17.6K | 114.5K |
Net Change In Cash | 6.18K | 79 | -60.75K | -849.96K | 911.88K | -56 | -8.82K | -126.66K |
Cash at end of period | 6.44K | 262 | 2.60K | 62.43K | 912.39K | 513 | 569 | 9.39K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |